Jagsonpal Pharmaceuticals Ltd
Healthcare | Small Cap
Jagsonpal Pharmaceuticals Ltd. presents a very strong financial profile, characterized by exceptional health in several key areas. The company has an outstanding ability to cover its short-term bills and is virtually debt-free, indicating a very low-risk financial structure. It demonstrates excellent profitability, efficiently converting sales into high profits, and has shown robust growth in both sales and earnings. This points to a healthy, well-managed core business. However, while the company's operations are very strong, the direct financial returns to shareholders, such as earnings and book value per share, are less impressive and appear average or weak. The future outlook is positive due to its solid foundation, but the value passed on to individual shareholders presents a different picture compared to its operational excellence.
Latest Report
View AllLatest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsOvervalued
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio10.00
- Financial Ratio5.00
- Profitability Ratio10.00
- Efficiency Ratio8.33
- Coverage Ratio8.40
- Solvency Ratio10.00
- Liquidity Ratio10.00
- Peer Assessment
- Management AssessmentBalanced
- Risk AssessmentBalanced
- 1 HourBullish
- 2 HoursBullish
- 4 HoursStrong Bullish
- 1 DayStrong Bullish
- 1 WeekBullish
- 1 MonthBullish
Jagsonpal Pharmaceuticals Ltd. presents a very strong financial profile, characterized by exceptional health in several key areas. The company has an outstanding ability to cover its short-term bills and is virtually debt-free, indicating a very low-risk financial structure. It demonstrates excellent profitability, efficiently converting sales into high profits, and has shown robust growth in both sales and earnings. This points to a healthy, well-managed core business. However, while the company's operations are very strong, the direct financial returns to shareholders, such as earnings and book value per share, are less impressive and appear average or weak. The future outlook is positive due to its solid foundation, but the value passed on to individual shareholders presents a different picture compared to its operational excellence.
Latest Report
View AllLatest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
Overall Valuation Score
P/E RATIO (TTM)
33.07
Industry Median
28.62
Small Cap Median
27.17
P/E RATIO
33.01
P/B RATIO
5.15
Industry Median
3.17
Small Cap Median
2.62
P/S RATIO
4.96
Industry Median
3.42
Small Cap Median
2.55
Others
PEG RATIO
1.56
EV/EBITDA RATIO
19.51
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹212.28 as on Jun 20, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
Concall Report⬤4th May 26
Q4 and FY26 Earnings Conference Call
BULLISH SENTIMENT
Quarterly Report⬤27th Apr 26
Financial Results for the Quarter and Year Ended March 31, 2026
UNDEFINED SENTIMENT
Concall Report⬤27th Jan 26
Q3 and nine months FY26 Earnings Conference Call
BULLISH SENTIMENT
Quarterly Report⬤21st Jan 26
Quarterly Financial Results Q3 FY 2025–26
NEUTRAL SENTIMENT
The company's growth profile is outstanding across the board. It has demonstrated very strong performance in increasing its revenue, operating profit, and bottom-line income over the analysis period. This growth is also reflected in the significant expansion of its asset base. Such consistent and high growth in all key financial areas is a very positive indicator, suggesting strong market demand, effective strategy, and a promising upward trajectory for the business.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 15.96 | 8.72 | -11.81 | 28.71 | 6.69 |
| Operating Profit Growth Rate | 36.84 | 30.77 | -32.35 | 121.74 | 13.73 |
| Earnings Per Share (EPS) Growth | 10.77 | 41.67 | -16.67 | 145.29 | -22.9 |
| Asset Growth Rate | 0 | 18.9 | 11.28 | 28.11 | 14.03 |
| Net Income Growth Rate | 11.76 | 42.11 | -18.52 | 150 | -21.82 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
This area highlights a less favorable aspect of the company's financial story. Key metrics that measure direct value to shareholders, such as earnings per share and the book value per share, are relatively weak. The dividends paid out are also at a moderate level. This suggests that despite the company's strong operational profitability and growth, the translation of this success into per-share value and returns for individual investors has been below average.
| Financial Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | 2.85 | 4.44 | 3.38 | 6.05 | 6.86 |
| Cash Earnings Per Share (Cash EPS) | 3.23 | 4.31 | 3.69 | 9.69 | 8 |
| Book Value Per Share | 20.46 | 24.46 | 28.77 | 36.92 | 42.46 |
| Dividend Per Share (DPS) | 1.61 | 2 | 2.01 | 2.5 | 3.99 |
| Capital Expenditures (CapEx) | 0.5 | 1 | 0.2 | 35.4 | 0.1 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
The company's profitability is outstanding across all measures. It is highly effective at generating profit from its sales, from the initial gross profit down to the final net profit. Furthermore, it delivers excellent returns on the capital provided by shareholders and on its total asset base. This comprehensive strength in profitability highlights a highly efficient and lucrative business model, serving as a key driver of its overall financial health and a significant positive for investors.
| Profitability Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Profit Margin | 11.01 | 13.92 | 10.05 | 15.99 | 17.07 |
| Return on Capital Employed (ROCE) | 20 | 25 | 17 | 23 | 23 |
| Return on Equity (ROE) | 14.29 | 16.98 | 11.76 | 22.92 | 15.58 |
| Return on Assets (ROA) | 15.85 | 17.44 | 10.6 | 18.35 | 18.3 |
| Operating Margin | 11.93 | 14.35 | 11 | 18.96 | 20.21 |
| Net Margin | 8.72 | 11.39 | 10.53 | 20.45 | 14.98 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
The company demonstrates strong operational efficiency in managing its working capital. It is particularly effective at selling its inventory quickly and collecting payments from customers without delay. These are significant strengths that contribute to healthy cash flow. However, a notable weakness is its effectiveness in using its total capital base to generate sales. This suggests that while specific day-to-day operations are efficient, the overall financial structure may not be as productive in generating revenue as it could be.
| Efficiency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio | 9.48 | 9.88 | 23.22 | 2.86 | 3.38 |
| Inventory Turnover Ratio | 6.47 | 8 | 10.44 | 15.07 | 15.87 |
| Receivables Turnover Ratio | 15.03 | 12.81 | 13.06 | 22.42 | 19.13 |
| Days Sales in Inventory Ratio | 56.41 | 45.62 | 34.96 | 24.22 | 23 |
| Receivable Days | 24.28 | 28.49 | 27.95 | 16.28 | 19.08 |
| Capital Turnover Ratio | 1.64 | 1.44 | 1.07 | 1.08 | 1.01 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
The company's ability to cover its financial obligations is strong, though it presents a mixed picture. Its capacity to meet interest payments on debt is excellent, which is expected given its very low debt levels and provides a high degree of safety. However, the cushion of earnings available to cover dividend payments to shareholders is only average. This suggests that while there is no risk regarding debt payments, the company's dividend policy is less comfortably supported by its profits.
| Coverage Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Interest Coverage Ratio | N/A | N/A | 31 | 71 | 59 |
| Equity Dividend Coverage Ratio | 1.79 | 2.04 | 1.69 | 3.33 | 1.61 |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
The company's long-term financial stability is exceptionally strong. It operates with almost no debt on its books, meaning it is financed almost entirely by the owners' capital (equity) and its own profits. This extremely low reliance on borrowing minimizes financial risk from interest rate changes and economic downturns. This conservative and stable financial structure is a significant strength, providing a solid foundation for the business, though it may also mean the company is not taking advantage of leverage to potentially accelerate growth.
| Solvency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debt Ratio | 0 | 0.04 | 0.05 | 0.04 | 0.03 |
| Debt to Equity Ratio | 0 | 0.04 | 0.05 | 0.04 | 0.03 |
| Equity Ratio | 1 | 0.96 | 0.95 | 0.96 | 0.97 |
| Debt To Asset Ratio | 0 | 0.03 | 0.04 | 0.03 | 0.03 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
The company's ability to meet its short-term financial obligations is exceptionally strong. It holds a very high level of cash and other liquid assets, far exceeding its immediate liabilities. This robust position means there is almost no risk of the company being unable to pay its bills on time. Such strong liquidity provides significant financial flexibility and stability, which is a major positive for its overall financial health. On the other hand, holding very high levels of cash could mean that these resources are not being invested for future growth.
| Liquidity Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Current Ratio | 2.94 | 5.67 | 9.9 | 6.34 | 7.22 |
| Quick Ratio | 1.97 | 4.97 | 9.19 | 5.83 | 6.75 |
| Cash Ratio | 0.81 | 3.83 | 7.05 | 4.45 | 3.31 |
| Operating Cash Flow Ratio | 0.23 | 1.57 | 1.67 | 1.9 | 1.47 |
Current Ratio
Quick Ratio
Cash Ratio
Operating Cash Flow Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Jagsonpal Pharmaceuticals Ltd | 8.51 | 33.01 | Overvalued | 58.00 | 6.42 | 43.00 |
| 2 | Amrutanjan Health Care Ltd | 8.25 | 77.37 | Highly Overvalued | 31.00 | 20.03 | 21.00 |
| 3 | Accent Microcell Ltd | 7.96 | 24.25 | Neutral | 57.00 | 18.28 | 44.00 |
| 4 | Windlas Biotech Ltd | 7.52 | 25.92 | Neutral | 105.00 | 32.19 | 66.00 |
| 5 | Lincoln Pharmaceuticals Ltd | 7.31 | 14.01 | Neutral | 98.00 | 43.88 | 88.00 |
| 6 | NGL Fine Chem Ltd | 6.98 | 39.22 | Overvalued | 73.00 | 67.39 | 48.00 |
| 7 | Syncom Formulations (India) Ltd | 6.92 | 17.27 | Undervalued | 77.00 | 0.81 | 76.00 |
| 8 | Kilitch Drugs (India) Ltd | 6.61 | 21.54 | Neutral | 37.00 | 9.27 | 30.00 |
| 9 | Kopran Ltd | 6.60 | 25.82 | Neutral | 62.00 | 6.30 | 26.00 |
| 10 | Hester Biosciences Ltd | 6.54 | 31.74 | Neutral | 87.00 | 61.24 | 57.00 |
| 11 | Sigachi Industries Ltd | 6.49 | 11.55 | Highly Undervalued | 54.00 | -2.08 | -83.00 |
| 12 | Sakar Healthcare Ltd | 5.81 | 58.66 | Highly Overvalued | 69.00 | 13.70 | 30.00 |
| 13 | Remus Pharmaceuticals Ltd | 5.31 | 25.48 | Neutral | 57.00 | 20.97 | 46.00 |
| 14 | Ind-Swift Laboratories Ltd | 4.95 | 39.28 | Neutral | 45.00 | 4.89 | 41.00 |
| 15 | Venus Remedies Ltd | 4.83 | 23.37 | Neutral | 147.00 | 74.30 | 103.00 |
| 16 | Wanbury Ltd | 4.65 | 28.62 | Neutral | 88.00 | 18.93 | 43.00 |
| 17 | Solara Active Pharma Sciences Ltd | 4.34 | -274.68 | Neutral | 187.00 | -1.50 | -7.00 |
Management effectiveness is mixed. The company demonstrates excellent financial prudence, reflected in its negligible debt, consistent dividend payouts, and strong shareholder returns (ROCE/ROE). Promoter confidence remains high, and increasing FII interest is a positive signal. However, these strengths are significantly counterbalanced by poor operational consistency. The company has experienced a recent decline in annual sales and profits, coupled with high volatility in quarterly earnings. Furthermore, a notable portion of profit in the latest fiscal year originated from non-core 'Other Income,' raising questions about the sustainability of core operational earnings. This creates a dichotomy of strong financial management against weak and inconsistent business performance.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | ROCE (TTM) | 33.14% | Excellent capital return |
| Debt to Equity | 0.05 | Negligible financial risk | |
| CONS | Sales Growth (FY24) | -11.83% | Declining core business |
| Earnings Quality | 30% of PBT from Other Income | Unreliable profit source |
Financial Performance & Growth
The company's financial performance is rated as weak due to significant inconsistency and recent negative trends. While long-term compounded growth appears strong, the most recent performance indicates a sharp reversal. For the fiscal year ending March 2024, sales declined by 11.83% and net profit fell by 21.50%. This downturn follows several years of robust growth, highlighting performance volatility. Quarterly results further underscore this instability, with YOY sales growth fluctuating from over 50% to negative double digits in recent periods. The Operating Profit Margin (OPM) also shows this pressure, dropping to 11% in FY24 from 14% in FY23. Additionally, a substantial portion of pre-tax profit in FY24 (30%) was derived from 'Other Income', indicating a reliance on non-core activities rather than sustainable operational strength.
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Sales Growth (%) | -4.95% | 18.53% | 15.76% | 8.79% | -11.83% |
| Profit Growth (%) | 9.28% | 116.22% | 7.62% | 55.83% | -21.50% |
Capital Efficiency & Returns
Management has demonstrated an excellent capability in generating returns on invested capital. The current Trailing Twelve Months (TTM) Return on Capital Employed (ROCE) stands at an outstanding 33.14%, and Return on Equity (ROE) is 28.51%. These figures are significantly above the industry median and the company's own recent historical averages. The annual ROCE has shown a strong upward trend over the past five years, rising from 9% in FY20 to a peak of 25% in FY23 before moderating to a still-healthy 17% in FY24. This performance indicates that management is highly effective at utilizing its capital base to generate profits for shareholders, a clear operational strength despite the volatility in top-line growth.
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|
| ROCE (%) | 9% | 18% | 20% | 25% | 17% | 33.14% |
Financial Health & Prudence
The company's financial health is excellent, reflecting a highly prudent approach to capital management. The balance sheet is exceptionally strong, with a negligible Debt to Equity ratio of 0.05 as of March 2024. The company was effectively debt-free in FY22, and current borrowings are minimal. This low leverage minimizes financial risk and provides significant flexibility. The company has also shown a commitment to sharing profits with shareholders, maintaining a consistent and healthy Dividend Payout Ratio, which stood at a strong 59% in FY24. This combination of a robust, low-debt balance sheet and a shareholder-friendly dividend policy demonstrates outstanding financial prudence and stability.
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Debt/Equity Ratio | 0.05 | 0.06 | 0.00 | 0.04 | 0.05 |
| Dividend Payout % | 17% | 15% | 56% | 49% | 59% |
Shareholding & Ownership Structure
The shareholding structure is a positive indicator of management and investor confidence. Promoter holding is strong, standing at 68.09% as of March 2024. While this represents a slight dilution from over 70% in prior years, it remains a substantial stake, indicating that the interests of the management are well-aligned with those of other shareholders. Furthermore, there is a clear trend of increasing interest from Foreign Institutional Investors (FIIs). FII holding has grown from zero in FY22 to 0.73% by March 2024, suggesting increasing external confidence in the company's long-term prospects. This high promoter stake combined with the positive FII trend reflects a strong and stable ownership structure.
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|
| Promoter Holding % | 70.34% | 70.34% | 68.71% | 68.72% | 68.09% |
| FII Holding % | 0.00% | 0.00% | 0.00% | 0.10% | 0.73% |
The primary risk stems from the quality and volatility of its earnings. While financial health is robust with almost no debt, the core business operations show signs of instability. The recent fiscal year saw a decline in both sales and profits, and quarterly results are highly erratic. A significant portion of FY24 pre-tax profit was generated from non-core 'Other Income,' which is not a sustainable or predictable source. Furthermore, the presence of large 'Exceptional Items' in the past introduces additional uncertainty into the financial statements. These factors combine to create a risk profile where, despite a strong balance sheet, the predictability and strength of core operational earnings are questionable.
Earnings Quality & Volatility
The quality of the company's earnings is a significant concern. In FY24, 'Other Income' accounted for ₹9 Cr of the ₹30 Cr in Profit Before Tax, representing a 30% contribution from non-operational sources. This reliance obscures the true performance of the core business. The issue is compounded by a history of large, irregular 'Exceptional Items,' such as a ₹12.8 Cr gain in FY17 and a -₹2.51 Cr loss in FY23, which distort year-on-year comparisons. This accounting unpredictability is mirrored in the extreme volatility of quarterly operational results, making future performance difficult to forecast.
Operational Performance
There is a notable risk in the company's recent operational performance. After a period of growth, the business experienced a significant downturn in FY24, with annual sales declining by 11.83% and net profit falling by 21.50%. This reversal indicates potential challenges in the company's market or execution strategy. The decline in profitability is also evident in the Operating Profit Margin (OPM), which compressed from 14% in FY23 to 11% in FY24. This shows that the company's ability to generate profit from its core operations has weakened recently.
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10212.05Bullish
- SMA 20210.62Bullish
- SMA 50210.56Bullish
- EMA 10212.11Bullish
- EMA 20211.31Bullish
- EMA 50209.82Bullish
- DEMA 10213.14Bearish
- DEMA 20212.40Bullish
- DEMA 50212.03Bullish
- TEMA 10213.49Bearish
- TEMA 20212.78Bullish
- TEMA 50212.64Bullish
- MACD0.90Bullish
- ADX41.91Strong Trend
- IndicatorValueSignal
- RSI59.18Neutral
- CCI97.15Neutral
- ROC 91.10Bullish
- ROC 142.40Bullish
- ROC 251.99Bullish
- Stoch K82.19Overbought
- Stoch D87.62Overbought
- IndicatorValueSignal
- BB Upper214.08Neutral
- BB Middle210.62Neutral
- BB Lower207.16Neutral
- ATR2.22High Volatility
- IndicatorValueSignal
- MFI65.50Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 2 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10210.87Bullish
- SMA 20210.73Bullish
- SMA 50207.15Bullish
- EMA 10211.54Bullish
- EMA 20210.56Bullish
- EMA 50208.50Bullish
- DEMA 10212.62Bullish
- DEMA 20212.29Bullish
- DEMA 50210.75Bullish
- TEMA 10213.10Bearish
- TEMA 20212.40Bullish
- TEMA 50212.09Bullish
- MACD1.28Bullish
- ADX49.74Strong Trend
- IndicatorValueSignal
- RSI59.81Neutral
- CCI78.42Neutral
- ROC 91.91Bullish
- ROC 141.62Bullish
- ROC 251.45Bullish
- Stoch K89.15Overbought
- Stoch D81.28Overbought
- IndicatorValueSignal
- BB Upper214.17Neutral
- BB Middle210.73Neutral
- BB Lower207.29Neutral
- ATR3.01High Volatility
- IndicatorValueSignal
- MFI64.32Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 4 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10210.80Bullish
- SMA 20208.17Bullish
- SMA 50205.88Bullish
- EMA 10210.69Bullish
- EMA 20209.05Bullish
- EMA 50206.69Bullish
- DEMA 10212.47Bullish
- DEMA 20211.44Bullish
- DEMA 50210.16Bullish
- TEMA 10212.64Bullish
- TEMA 20212.74Bullish
- TEMA 50N/AN/A
- MACD1.90Bullish
- ADX30.92Strong Trend
- IndicatorValueSignal
- RSI59.54Neutral
- CCI75.86Neutral
- ROC 90.99Bullish
- ROC 143.90Bullish
- ROC 256.23Bullish
- Stoch K55.97Neutral
- Stoch D53.16Neutral
- IndicatorValueSignal
- BB Upper216.62Neutral
- BB Middle208.17Neutral
- BB Lower199.72Neutral
- ATR4.38Low Volatility
- IndicatorValueSignal
- MFI78.94Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Market Sentiment
Analysis Driven By 33 Technical Indicators From The 1 Day Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10208.03Bullish
- SMA 20206.56Bullish
- SMA 50204.28Bullish
- SMA 100190.16Bullish
- SMA 200201.68Bullish
- EMA 10208.98Bullish
- EMA 20207.33Bullish
- EMA 50202.74Bullish
- EMA 100199.25Bullish
- EMA 200201.84Bullish
- DEMA 10211.17Bullish
- DEMA 20209.87Bullish
- DEMA 50209.80Bullish
- DEMA 100199.95Bullish
- DEMA 200196.56Bullish
- TEMA 10212.25Bullish
- TEMA 20209.85Bullish
- TEMA 50212.93Bearish
- TEMA 100208.47Bullish
- TEMA 200190.49Bullish
- MACD2.04Bullish
- ADX17.89Weak Trend
- IndicatorValueSignal
- RSI58.91Neutral
- CCI89.80Neutral
- ROC 145.30Bullish
- ROC 252.41Bullish
- Stoch K60.73Neutral
- Stoch D58.97Neutral
- IndicatorValueSignal
- BB Upper214.80Neutral
- BB Middle206.56Neutral
- BB Lower198.32Neutral
- ATR6.75Low Volatility
- IndicatorValueSignal
- MFI67.39Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 21 Technical Indicators From The 1 Week Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
- IndicatorValueSignal
- SMA 20190.66Bullish
- SMA 50209.05Bullish
- EMA 20199.27Bullish
- EMA 50202.21Bullish
- DEMA 20201.22Bullish
- DEMA 50199.23Bullish
- TEMA 20209.67Bullish
- TEMA 50189.96Bullish
- MACD2.76Bullish
- ADX20.58Weak Trend
- IndicatorValueSignal
- RSI53.84Neutral
- CCI-1.36Neutral
- ROC 1421.95Bullish
- ROC 255.37Bullish
- Stoch K72.72Neutral
- Stoch D73.08Neutral
- IndicatorValueSignal
- BB Upper222.64Neutral
- BB Middle190.67Neutral
- BB Lower158.69Neutral
- ATR15.77High Volatility
- IndicatorValueSignal
- MFI86.45Overbought
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 25 Technical Indicators From The 1 Month Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 6188.52Bullish
- SMA 12210.95Bearish
- SMA 24210.31Bearish
- EMA 6199.22Bullish
- EMA 12203.22Bullish
- EMA 24198.59Bullish
- DEMA 6196.43Bullish
- DEMA 12199.68Bullish
- DEMA 24218.21Bearish
- TEMA 6201.15Bullish
- TEMA 12190.04Bullish
- TEMA 24205.57Bullish
- MACD31.05Bearish
- ADX36.12Strong Trend
- IndicatorValueSignal
- RSI54.69Neutral
- CCI58.61Neutral
- ROC 2542.86Bullish
- ROC 5064.73Bullish
- Stoch K45.59Neutral
- Stoch D54.52Neutral
- IndicatorValueSignal
- BB Upper286.56Neutral
- BB Middle221.61Neutral
- BB Lower156.65Neutral
- ATR41.51Low Volatility
- IndicatorValueSignal
- MFI76.53Neutral